Furthermore, within the b-DMARDs-induced Rem/RA sub-group, 36 (65%) RA patients were treated with TNFi, 12 (22%) with anti-IL6R, and 7 (13%) with anti-CTLA4-Ig respectively. This evidence concerns the gene IL6R and rheumatoid arthritis.